Citations

Clear

1526 citation(s) found for "Sun, Bo".

Abstract 5358: BRCA1 is a negative modulator of the PRC2 complex.
Zeng, Xianzhou , Chen, Shuai , Wang, Lan , Huang, Haojie

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 5358-5358

10.1158/1538-7445.am2013-5358 Get It

Abstract The Polycomb repressive complex 2 (PRC2) is important for maintenance of stem cell pluripotency and suppression of cell differentiation by promoting histone H3 lysine 27 trimethylation (H3K27me3) and transcriptional repression of differentiation regulatory genes. Here we show that the tumor suppressor protein BRCA1 interacts with EZH2 and other components of PRC2 in mouse embryonic stem (ES) and human breast cancer cells. The BRCA1-binding region in EZH2 overlaps with the non-coding RNA (ncRNA)-binding domain, and BRCA1 expression inhibits the binding of EZH2 to the HOTAIR ncRNA. Decreased expression of BRCA1 causes EZH2 re-targeting genome wide and elevates H3K27me3 levels at PRC2 target loci in both mouse ES and human breast cancer cells. BRCA1 deficiency blocks ES cell differentiation and enhances breast cancer migration and invasion in an EZH2-dependent manner. These results reveal that BRCA1 is a key negative modulator of PRC2 and that loss of BRCA1 inhibits ES cell differentiation and enhances cancer aggressive phenotypes via augmented PRC2 function. Citation Format: Xianzhou Zeng, Shuai Chen, Lan Wang, Haojie Huang. BRCA1 is a negative modulator of the PRC2 complex. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5358. doi:10.1158/1538-7445.AM2013-5358
Abstract P1-05-24: Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borgés, Sahra, Döppler, Heike, Andorfer, CA, Perez, EA, Anastasiadis, PZ, Thompson, AE, Geiger, XJ, Störz, Peter , Andorfer, Cathy, Sun, Zhifu

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 72 | Issue: 24_Supplement | Pages: P1-05-24-P1-05-24

10.1158/0008-5472.sabcs12-p1-05-24 Get It

Abstract Epigenetic silencing of tumor suppressing genes by promoter-specific DNA methylation is common in many types of cancer. As an early event, this process has been well shown to promote tumor initiation and progression; however little is known how such epigenetic silencing can contribute to tumor metastasis. The PRKD1 gene encodes Protein Kinase D1 (PKD1), a serine/threonine kinase expressed in epithelial cells of the normal mammary gland that maintains the epithelial phenotype of normal breast cells and prevents epithelial-to-mesenchymal transition (EMT). PKD1 is also a critical suppressor of tumor cell invasion and is silenced in expression and activity during breast tumor progression. Here, we show that aberrant methylation of PRKD1 promoter region is not only correlated with the silencing of its expression but is also associated with invasiveness of breast cancer cell lines and with aggressiveness of breast tumors. Using the highly invasive MDA-MB-231 cells, we show that the inhibition of PRKD1 promoter methylation with the DNA methyltransferase inhibitor decitabine restores PKD1 expression and significantly decreases their invasive abilities in vitro. More importantly, in a tumor xenograft model it dramatically blocks tumor spread and metastasis to the lung in a PKD1-dependent fashion. Our data suggest that the status of epigenetic regulation of the PRKD1 promoter can provide valid information on the invasiveness of breast tumors, and therefore could serve as an early diagnostic marker. Moreover, targeted upregulation of PKD1 expression may be used as a therapeutic approach to reverse the invasive phenotype of breast cancer cells. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-05-24.
The Cistrome and Gene Signature of Androgen Receptor Splice Variants in Castration Resistant Prostate Cancer Cells
Ji, Lu , Lonergan, Peter E. , Nacusi, Lucas P., Wang, Liguo , Schmidt, Lucy J., Sun, Zhifu , Steen, Travis Van der, Boorjian, Stephen A. , Kosari, Farhad , Vasmatzis, George , Klee, George G., Wang, Chunxi , Tindall, Donald J., Lu, Ji, van der Steen, Travis, Balk, Steven P. , Huang, Haojie , Sun, Zhifu , Wang, Liguo

Mayo Clinic

Journal of Urology | August 14, 2014 | Volume: 193 | Issue: 2 | Pages: 690-698

10.1016/j.juro.2014.08.043 | PMID 25132238 Get It

Dynamics of Leukemia Stem-like Cell Extinction in Acute Promyelocytic Leukemia
Werner, Benjamin , Gallagher, Robert E. , Paietta, Elisabeth , Litzow, Mark R. , Tallman, Martin S. , Wiernik, Peter H. , Slack, James L., Sun, Zhuoxin , Traulsen, Arne , Dingli, David , Willman, Cheryl L. , Dingli, David

Mayo Clinic

Cancer Research | August 1, 2014 | Volume: 74 | Issue: 19 | Pages: 5386-5396

10.1158/0008-5472.can-14-1210 | PMID 25082816 Get It

Abstract Many tumors are believed to be maintained by a small number of cancer stem–like cells, where cure is thought to require eradication of this cell population. In this study, we investigated the dynamics of acute promyelocytic leukemia (APL) before and during therapy with regard to disease initiation, progression, and therapeutic response. This investigation used a mathematical model of hematopoiesis and a dataset derived from the North American Intergroup Study INT0129. The known phenotypic constraints of APL could be explained by a combination of differentiation blockade of PML–RARα–positive cells and suppression of normal hematopoiesis. All-trans retinoic acid (ATRA) neutralizes the differentiation block and decreases the proliferation rate of leukemic stem cells in vivo. Prolonged ATRA treatment after chemotherapy can cure patients with APL by eliminating the stem-like cell population over the course of approximately one year. To our knowledge, this study offers the first estimate of the average duration of therapy that is required to eliminate stem-like cancer cells from a human tumor, with the potential for the refinement of treatment strategies to better manage human malignancy. Cancer Res; 74(19); 5386–96. ©2014 AACR.
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Zeidan, Amer M. , Lee, Ju‐Whei, Prébet, Thomas , Greenberg, Peter L. , Sun, Zhuoxin , Juckett, Mark, Smith, Mitchell R. , Paietta, Elisabeth , Gabrilove, Janice , Katterling, Rhett P., Tallman, Martin S. , Gore, Steven D. , Lee, Ju‐Whei , Erba, Harry Paul , Prebet, Thomas , Zeidan, Amer M

Mayo Clinic

British Journal of Haematology | July 4, 2014 | Volume: 167 | Issue: 1 | Pages: 62-68

10.1111/bjh.13008 | PMID 24995683 Get It

SummaryReliable clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving response and survival advantage in a Dutch cohort. To validate this observation, we analysed a larger cohort of North American patients, whose data was collected in a prospective clinical trial with a longer median follow‐up. We found a significant association between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among patients with MDS or oligoblastic acute myeloid leukaemia (<30% bone marrow blasts, n = 102), there was a statistically significant reduction in risk of death for patients who achieved platelet count doubling (n = 23, median OS, 21·0 months) compared to those who did not (n = 79, median OS, 16·7 months, adjusted hazard ratio (no/yes)=1·88, 95% confidence interval, 1·03–3·40, P = 0·04). Nonetheless, the addition of this platelet count doubling variable did not improve the survival prediction provided by the revised International Prognostic Scoring System or the French Prognostic Scoring System. Identification of reliable and consistent predictors for clinical benefit for azacitidine therapy remains an unmet medical need and a top research priority.
Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease
Hill, David , Schwarz, Adam J. , Isaac, Maria , Pani, Luca , Vamvakas, Spiros, Hemmings, Robert , Carrillo, María C. , Yu, Peng , Sun, Jia , Boccardi, Marina , Brewer, James B., Brumfield, Martha A., Cantillon, Marc, Cole, Patricia E., Fox, Nick C. , Frisoni, Giovanni B. , Kelleher, Thomas, Luo, Feng , Novak, Gerald , Maguire, Paul, Meibach, Richard C., Patterson, Patricia, Bain, Lisa J. , Raunig, David , Soares, Holly , Suhy, Joyce, Wang, Huanli , Wolz, Robin, Stephenson, Diane , Boccardi, Marina , Frisoni, Giovanni B. , Beckett, Laurel , Jack, Clifford R. , Maguire, Paul, Sampaio, Cristina , Fox, Nick C

Mayo Clinic

Alzheimer's & Dementia | June 28, 2014 | Volume: 10 | Issue: 4 | Pages: 421

10.1016/j.jalz.2013.07.003 | PMID 24985687 Get It

AbstractBackgroundRegulatory qualification of a biomarker for a defined context of use provides scientifically robust assurances to sponsors and regulators that accelerate appropriate adoption of biomarkers into drug development.MethodsThe Coalition Against Major Diseases submitted a dossier to the Scientific Advice Working Party of the European Medicines Agency requesting a qualification opinion on the use of hippocampal volume as a biomarker for enriching clinical trials in subjects with mild cognitive impairment, incorporating a scientific rationale, a literature review and a de novo analysis of Alzheimer's Disease Neuroimaging Initiative data.ResultsThe literature review and de novo analysis were consistent with the proposed context of use, and the Committee for Medicinal Products for Human Use released an opinion in November 2011.ConclusionsWe summarize the scientific rationale and the data that supported the first qualification of an imaging biomarker by the European Medicines Agency.
The HELIOS Trial Protocol: A Phase III Study of Ibrutinib in Combination with Bendamustine and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
Hallek, Michael , Österborg, Anders , Chanan‐Khan, Asher , Mahler, Michelle, Salman, Mariya, Wan, Ying , Sun, Steven , Zhuang, Sen Hong, Howes, Angela, Kay, Neil E.

Mayo Clinic

Future Oncology | June 5, 2014 | Volume: 11 | Issue: 1 | Pages: 51-59

10.2217/fon.14.119 | PMID 24901734 Get It

Non‐radiation endoscopic retrograde cholangiopancreatography in the management of choledocholithiasis during pregnancy
Wu, Wenming , Faigel, Douglas O. , Sun, Gang , Yang, Yunsheng

Mayo Clinic

Digestive Endoscopy | May 27, 2014 | Volume: 26 | Issue: 6 | Pages: 691-700

10.1111/den.12307 | PMID 24861135 Get It

Gallstone diseases are common during pregnancy. In most cases, patients are asymptomatic and do not require any treatment. However, choledocholithiasis, cholangitis, and gallstone pancreatitis may potentially become life‐threatening for both mother and fetus and often require urgent intervention. Although endoscopic retrograde cholangiopancreatography (ERCP) has become the standard technique for removing common bile duct stones, it is associated with ionizing radiation that could carry teratogenic risk. Non‐radiationERCP(NR‐ERCP) is reported to be effective without incurring this risk. Two techniques have been described to confirm bile duct cannulation: bile aspiration and image guidance. With bile aspiration, biliary cannulation is confirmed by applying suction to the cannula to yield bile, thus confirming an intrabiliary position. Image guidance involves using ultrasound or direct visualization (choledochoscopy) to confirm selective biliary cannulation or duct clearance. Once cannulation is achieved, the stones are removed using standardERCPtechniques and tools. Case series and retrospective studies have reported success rates of up to 90% forNR‐ERCPwith complication rates similar to standardERCP. Pregnancy outcomes are not adversely affected byNR‐ERCP, but whether the avoidance of radiation carries benefit for the baby is unknown. Prospective comparative trials are lacking.NR‐ERCPis technically demanding and should be attempted only by skilled biliary endoscopists in properly equipped and staffed health‐care institutions, in a multidisciplinary setting.
Peroxisome proliferator-activated receptor δ promotes colonic inflammation and tumor growth
Wang, Dingzhi , Fu, Lingchen, Guo, Lixia , Chaturvedi, Rupesh , Wilson, Keith T. , Wei, Ning , Sun, Xiaofei , Dey, Sudhansu K. , DuBois, Raymond N.

Mayo Clinic

Proceedings of the National Academy of Sciences | April 25, 2014 | Volume: 111 | Issue: 19 | Pages: 7084-7089

10.1073/pnas.1324233111 | PMID 24763687 Get It

Significance Our study not only reveals a novel role of peroxisome proliferator-activated receptor δ (PPARδ) in colonic inflammation and colitis-associated tumorigenesis, but also provides some rationale for development of PPARδ antagonists as new therapeutic agents in the treatment of inflammatory bowel disease and colitis-associated colorectal cancer. Moreover, our findings indicate that prostaglandin E 2 generated by chronic inflammation is a crucial mediator connecting chronic inflammation and colorectal carcinogenesis.